INKT news

Latest 1 stories · newest Nov 12, 2026

INKT

MiNK Reports Q3 Results, Sees First Product Revenue

MiNK Therapeutics generated its first pre-commercial revenue from the aggregation therapy agenT-797 during the third quarter. The company highlighted the advancement of its randomized ARDS trial and selection for a major ARPA-H program, which could drive future growth.

Earnings Nov 12, 2026 sentiment +0.60 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same INKT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/INKT/newsSTART FREE